314 related articles for article (PubMed ID: 23665966)
21. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
Triantos CK; Koukias NM; Nikolopoulou VN; Burroughs AK
Aliment Pharmacol Ther; 2011 Oct; 34(8):901-10. PubMed ID: 21883323
[TBL] [Abstract][Full Text] [Related]
22. Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis.
Ashraf I; Choudhary A; Arif M; Matteson ML; Hammad HT; Puli SR; Bechtold ML
Indian J Gastroenterol; 2012 Apr; 31(2):69-74. PubMed ID: 22528343
[TBL] [Abstract][Full Text] [Related]
23. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis.
Loftus EV; Harewood GC; Loftus CG; Tremaine WJ; Harmsen WS; Zinsmeister AR; Jewell DA; Sandborn WJ
Gut; 2005 Jan; 54(1):91-6. PubMed ID: 15591511
[TBL] [Abstract][Full Text] [Related]
24. Statin Use Is Associated With Improved Outcomes of Patients With Primary Sclerosing Cholangitis.
Stokkeland K; Höijer J; Bottai M; Söderberg-Löfdal K; Bergquist A
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1860-1866.e1. PubMed ID: 30448601
[TBL] [Abstract][Full Text] [Related]
25. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features.
Palmela C; Peerani F; Castaneda D; Torres J; Itzkowitz SH
Gut Liver; 2018 Jan; 12(1):17-29. PubMed ID: 28376583
[TBL] [Abstract][Full Text] [Related]
27. In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment.
Rudolph G; Gotthardt DN; Kloeters-Plachky P; Kulaksiz H; Schirmacher P; Stiehl A
Dig Dis Sci; 2011 Dec; 56(12):3624-30. PubMed ID: 21656181
[TBL] [Abstract][Full Text] [Related]
28. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival.
Rudolph G; Gotthardt D; Kloeters-Plachky P; Rost D; Kulaksiz H; Stiehl A
J Hepatol; 2010 Aug; 53(2):313-7. PubMed ID: 20472317
[TBL] [Abstract][Full Text] [Related]
29. [Primary sclerosing cholangitis. To slow progression and reduce carcinoma risk].
MMW Fortschr Med; 2006 Jun; 148(24):42-3. PubMed ID: 16850808
[No Abstract] [Full Text] [Related]
30. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ
Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223
[TBL] [Abstract][Full Text] [Related]
31. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
Qiu X; Ma J; Wang K; Zhang H
Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
[TBL] [Abstract][Full Text] [Related]
32. Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease.
Lu MJ; Qiu XY; Mao XQ; Li XT; Zhang HJ
Aliment Pharmacol Ther; 2018 Feb; 47(3):318-331. PubMed ID: 29205426
[TBL] [Abstract][Full Text] [Related]
33. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis.
Jess T; Lopez A; Andersson M; Beaugerie L; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1793-1800.e1. PubMed ID: 24907505
[TBL] [Abstract][Full Text] [Related]
34. Activity of Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis Predicts Poorer Clinical Outcomes.
Peverelle M; Paleri S; Hughes J; De Cruz P; Gow PJ
Inflamm Bowel Dis; 2020 Nov; 26(12):1901-1908. PubMed ID: 31944235
[TBL] [Abstract][Full Text] [Related]
35. Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease.
Manninen P; Karvonen AL; Laukkarinen J; Aitola P; Huhtala H; Collin P
Scand J Gastroenterol; 2015 Apr; 50(4):423-8. PubMed ID: 25636976
[TBL] [Abstract][Full Text] [Related]
36. Ursodeoxycholic acid for primary biliary cirrhosis.
Gong Y; Huang ZB; Christensen E; Gluud C
Cochrane Database Syst Rev; 2008 Jul; (3):CD000551. PubMed ID: 18677775
[TBL] [Abstract][Full Text] [Related]
37. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis.
Claessen MM; Lutgens MW; van Buuren HR; Oldenburg B; Stokkers PC; van der Woude CJ; Hommes DW; de Jong DJ; Dijkstra G; van Bodegraven AA; Siersema PD; Vleggaar FP
Inflamm Bowel Dis; 2009 Sep; 15(9):1331-6. PubMed ID: 19229982
[TBL] [Abstract][Full Text] [Related]
38. Colorectal Strictures in Patients With Inflammatory Bowel Disease Do Not Independently Predict Colorectal Neoplasia.
Axelrad JE; Faye A; Slaughter JC; Harpaz N; Itzkowitz SH; Shah SC
Inflamm Bowel Dis; 2022 Jun; 28(6):855-861. PubMed ID: 34319381
[TBL] [Abstract][Full Text] [Related]
39. Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis.
Arizumi T; Tazuma S; Isayama H; Nakazawa T; Tsuyuguchi T; Takikawa H; Tanaka A;
J Gastroenterol; 2022 Nov; 57(11):902-912. PubMed ID: 36068441
[TBL] [Abstract][Full Text] [Related]
40. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.
Sabino J; Vieira-Silva S; Machiels K; Joossens M; Falony G; Ballet V; Ferrante M; Van Assche G; Van der Merwe S; Vermeire S; Raes J
Gut; 2016 Oct; 65(10):1681-9. PubMed ID: 27207975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
